Pyridostigmine and Amifampridine for Myasthenia Gravis

Myasthenia Gravis Clinical Trial

— IMPACT-MG  

Official title:

IMproving Symptomatic Treatment With Pyridostigmine and Amifampridine: a Randomized Double-blinded, Placebo Controlled Crossover Trial in Patients With Myasthenia Gravis (IMPACT-MG)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05919407
• Other study ID #: NL78666.058.21
• Status: Recruiting
• Phase: Phase 3
• Start date: March 22, 2023
• Est. completion date: September 22, 2024

Study information

• Verified date: June 2023
• Source: Leiden University Medical Center
• Contact: Martijn R. Tannemaat, MD, PhD
• Phone: +31715262197
• Email: m.r.tannemaat[@]lumc.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized, double-blind, placebo controlled, crossover intervention study evaluating the effect of pyridostigmine (part 1) and amifampridine (part 2) in Myasthenia Gravis (MG).

Description:

In the first part of the study, patients who are currently using pyridostigmine will be randomly allocated to one of two consecutive treatment periods in which patients either first receive placebo and then their usual dose of pyridostigmine, or vice versa. Each treatment period lasts 5 days with a 2-day wash-out period between each treatment period. Measurements will be performed at every last day of a treatment period (day 5 and day 12). In the second part of the study the effect of two doses of amifampridine as add-on to pyridostigmine will be studied. Patients will be randomly assigned to either one of three treatment sequences; 1) amifampridine 30 mg - amifampridine 60 mg - placebo or 2) amifampridine 60 mg - placebo - amifampridine 30 mg or 3) placebo - amifampridine 30 mg - amifampridine 60 mg. Again, each treatment period consists of 5 days and will be separated by a 2-day wash-out period. Measurements will be performed at every last day of treatment (day 19, day 26 and day 33). Patients will have the option to participate in a substudy to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of amifampridine in AChR positive MG patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: September 22, 2024
• Est. primary completion date: September 22, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age >18 years

2. AChR positive myasthenia gravis (ocular or generalized)

3. Current use of pyridostigmine

4. MGFA Clinical Classification I-IV

5. Receiving a stable dose of MG treatment (other than pyridostigmine). If applicable:

1. A stable steroid regimen for 1 month

2. Nonsteroidal immunosuppressants: i. Azathioprine, mycophenolate mofetil, cyclosporine or other nonsteroid immunosuppressive agents start > 3 months ago and a stable regimen for 1 month. ii. Rituximab start > 6 months ago, complement inhibitors and Fc receptor inhibitors start > 6 months ago and a stable regimen for 3 months. Additional inclusion criteria for part 2 To be eligible for participation in part 2 of the study patients must score >10 points on the MGII questionnaire at inclusion. We will include a maximum of 5 patients with a MGFA class I (i.e. 20 percent of the total number of included patients) to ensure that this study accurately reflects the clinical population.

Exclusion Criteria:

1. Use of intravenous immunoglobulin or plasma exchange <4 weeks or planned during the trial.

2. Thymectomy < 6 months, or thymectomy (expected) to take place during the trial

3. Use of other acetylcholinesterase inhibitors than pyridostigmine

4. Pregnancy, lactation or intention to become pregnant during the study

5. Treatment with amifampridine is contraindicated. Contraindications include a history of epilepsy, uncontrolled asthma, inherited QT syndrome / a prolonged QT interval (as indicated by ECG), any drug known to cause QT c-prolongation, any drug known to lower the epileptic threshold, a known hypersensitivity reaction to the active substance or to any of the excipients.

6. The patient is unable to fill out the study questionnaires or be interviewed in Dutch, or is unable to undergo the tests needed for the study, or is unable to give informed consent for participation in the study.

7. The investigator can exclude patients for this trial which are deemed not suitable for any reason.

Related Conditions & MeSH terms

• Muscle Weakness
• Myasthenia Gravis

Intervention

Drug:
• Pyridostigmine
Participants will receive pyridostigmine 10 mg tablets.
• Amifampridine (base) with modified release
Participants will receive amifampridine (base) with modified release 15 mg or 30 mg tablets.
• Placebo
The placebo tablets will be identical apart from the active substance (pyridostigmine)
• Placebo
The placebo tablets will be identical apart from the active substance (amifampridine base)

Locations

Country	Name	City	State
Netherlands	Leiden University Medical Center	Leiden	South-Holland

Sponsors (2)

Lead Sponsor	Collaborator
Leiden University Medical Center	NMD Pharma A/S

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	A clinically relevant change in Myasthenia Gravis Impairment Index (MGII) compared to placebo.		Assessed on Day 1, Day 5, Day 12, Day 19, Day 26 and Day 33 (cross-over),
Secondary	Change on 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9) compared to placebo		Assessed on Day 5, Day 12, Day 19, Day 26 and Day 33 (cross-over),
Secondary	Change on the 15-item revised version of the Myasthenia Gravis Quality of Life questionnaire (MG-QoL15r) compared to placebo		Assessed on Day 1, Day 5, Day 12, Day 19, Day 26 and Day 33 (cross-over),
Secondary	A clinically relevant change (=2 points change) on the Myasthenia Gravis Activities of Daily Living (MG-ADL) score compared to placebo.		Assessed on Day 1, Day 5, Day 12, Day 19, Day 26 and Day 33 (cross-over),
Secondary	A clinically relevant change (=3 points change) on the Quantitative Myasthenia Gravis (QMG) score compared to placebo.		Assessed on Day 1, Day 5, Day 12, Day 19, Day 26 and Day 33 (cross-over),
Secondary	Number of patients not able to complete first wash-out period due to an increase in myasthenic symptoms.		Assessed on Day 1 (crossover)
Secondary	Number of times escape medication is used (including effect on symptoms)		Assessed on Day 1, Day 5 and Day 12 (cross-over),
Secondary	Trough concentrations of pyridostigmine and amifampridine		Assessed on Day 1, Day 5, Day 12, Day 19, Day 26 and Day 33 (cross-over),
Secondary	Peak Plasma Concentration (Cmax)		Assessed on Day 19, Day 26 and Day 33 (cross-over),
Secondary	Area under the concentration-time curve (AUC0-8)		Assessed on Day 19, Day 26 and Day 33 (cross-over),
Secondary	Time of maximum concentration (Tmax)		Assessed on Day 19, Day 26 and Day 33 (cross-over),
Secondary	Serum half-life (T1/2)		Assessed on Day 19, Day 26 and Day 33 (cross-over),
Secondary	Trough concentration (Ctrough)		Assessed on Day 19, Day 26 and Day 33 (cross-over),
Secondary	Dose-response between serum concentrations of amifampridine and hand grip strength as measured with hand-held dynamometer.		Assessed on Day 19, Day 26 and Day 33 (cross-over),
Secondary	Utility as assessed by the 5-level EQ-5D (EQ-5D-5L)		Assessed on Day 1, Day 5, Day 12, Day 19, Day 26 and Day 33
Secondary	Healthcare use as assessed by the adapted iMCQ (iMTA Medical Consumption Questionnaire)	The iMCQ is adapted by omitting the modules on medication and travel. The recall period for the iMCQ is set to 12 months.	Assessed on Day 1
Secondary	Productivity as assessed by the adapted iPCQ (iMTA Productivity Cost Questionnaire)	The recall period for the iPCQ is set to 3 months.	Assessed on Day 1